Detalhe da pesquisa
1.
Association of indicators of extensive disease and rifampin-resistant tuberculosis treatment outcomes: an individual participant data meta-analysis.
Thorax
; 79(2): 169-178, 2024 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38135489
2.
Efficacy and Tolerability of Concomitant Use of Bedaquiline and Delamanid for Multidrug- and Extensively Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis.
Clin Infect Dis
; 76(7): 1328-1337, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36331978
3.
Association Between Increased Linezolid Plasma Concentrations and the Development of Severe Toxicity in Multidrug-Resistant Tuberculosis Treatment.
Clin Infect Dis
; 76(3): e947-e956, 2023 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35717636
4.
Occurrence of extrapulmonary tuberculosis is associated with geographical origin: spatial characteristics of the Frankfurt TB cohort 2013-2018.
Infection
; 51(3): 679-687, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36181634
5.
Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006-2019.
Emerg Infect Dis
; 28(9): 1796-1804, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35997386
6.
Evidence-based Definition for Extensively Drug-Resistant Tuberculosis.
Am J Respir Crit Care Med
; 204(6): 713-722, 2021 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34107231
7.
Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.
Clin Infect Dis
; 71(4): 905-913, 2020 08 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32797222
8.
Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.
Clin Infect Dis
; 71(4): e1-e36, 2020 08 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32628747
9.
Fully weekly antituberculosis regimen: a proof-of-concept study.
Eur Respir J
; 56(3)2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32430417
10.
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.
Eur Respir J
; 56(1)2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32636299
11.
Poor Performance of Rapid Molecular Tests to Define Eligibility for the Shortcourse Multidrug-resistant Tuberculosis Regimen.
Clin Infect Dis
; 68(8): 1410-1411, 2019 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30239638
12.
Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis.
Emerg Infect Dis
; 25(5): 936-943, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31002070
13.
Reduced critical concentration might not have improved MGIT-based DST's sensitivity to rifampicin.
Antimicrob Agents Chemother
; 68(5): e0170123, 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38534101
14.
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Lancet
; 392(10150): 821-834, 2018 09 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30215381
15.
Optimal management of drug-resistant tuberculosis: Can India lead the way?
Indian J Med Res
; 157(2&3): 220-222, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37202941
16.
Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis.
Eur Respir J
; 49(3)2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28182570
17.
Rifapentine access in Europe: growing concerns over key tuberculosis treatment component.
Eur Respir J
; 59(5)2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35589114
18.
The coming-of-age of bedaquiline: a tale with an open ending.
Eur Respir J
; 57(6)2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34112716
19.
Defining optimal fluoroquinolone exposure against Mycobacterium tuberculosis: contribution of murine studies.
Eur Respir J
; 57(4)2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33795357
20.
Impact of the revised definition of extensively drug-resistant tuberculosis.
Eur Respir J
; 58(2)2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33926973